Security key
92532F100
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)
CUSIP: 92532F100
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 346,069
- Total 13F value
- $180,821,175
- Share change
- +4,509
- SEC-reported price per share
- $522.81
- Number of holders
- 66
- Value change
- +$2,339,948
- Number of buys
- 33
- Number of sells
- 19
- Shares outstanding
- 254,406,089
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
66
Top holders
10
VRTX full security history
Ownership snapshot
Full 13F holder table
VERTEX PHARMACEUTICALS INC / MA SEC filings
VERTEX PHARMACEUTICALS INC / MA company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92532F100
Recent filing periods:
Ownership snapshot
Top reported holders of VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Capital World Investors
Disclosed value leader
Capital World Investors
Comparable rows
15/15
Latest evidence
21 Jul 2026
13F
13D/G
3/4/5
Lead comparable stake: 10%
13D/G row: Capital World Investors
Showing 1-6 of 15 holder rows.
Quick read
Capital World Investors leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Capital World Investors's linked filing trail.
Comparable ownership
Top 5
Capital World Investors
10%
Capital Research Global Investors
8.3%
VANGUARD CAPITAL MANAGEMENT LLC
7.5%
FMR LLC
3.6%
Reshma Kewalramani
0.04%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Capital World Investors |
13F
13D/G
Company
|
10%
from 13D/G
|
$12,972,221,775
26,115,014 shares
|
— | 30 Jun 2026 |
| Capital Research Global Investors |
13F
13D/G
Company
|
8.3%
from 13D/G
|
$9,681,703,171
19,490,637 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
7.5%
|
$8,500,369,377
19,036,076 shares
|
$0 | 31 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
3.6%
|
$4,642,686,284
9,220,827 shares
|
$0 | 31 Dec 2024 |
| Reshma Kewalramani |
3/4/5
CEO & President, Director
|
0.04%
|
$48,839,252
98,278 shares
|
-$19,738,855 | 27 Feb 2026 |
| Amit Sachdev |
3/4/5
EVP Chief Patient & Ext Af Off
|
0.03%
|
$36,773,417
74,031 shares
|
-$28,377,385 | 21 Jul 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
66
Shares
346,069
Rows available
66
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
1,758
Q3 2026 holders
66
Holder diff
-1,692
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend